Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration

Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, Diana V. Do, Julia A. Haller, Roberto Pili, Ingrid E. Zimmer-Galler, Kashif Janjua, R. C Andrew Symons, Peter A. Campochiaro

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration. Design: Nonrandomized clinical trial. Methods: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV. Results: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 μm. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement from baseline (P = .005), median foveal thickness was 248 μm representing a 72% reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91%, 88%, and 87%), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43%. Conclusions: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume145
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Fluorescein
Diabetic Retinopathy
Intravenous Infusions
Visual Acuity
Bevacizumab
Outcome Assessment (Health Care)
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration. / Nguyen, Quan Dong; Shah, Syed Mahmood; Hafiz, Gulnar; Do, Diana V.; Haller, Julia A.; Pili, Roberto; Zimmer-Galler, Ingrid E.; Janjua, Kashif; Symons, R. C Andrew; Campochiaro, Peter A.

In: American Journal of Ophthalmology, Vol. 145, No. 2, 02.2008.

Research output: Contribution to journalArticle

Nguyen, Quan Dong ; Shah, Syed Mahmood ; Hafiz, Gulnar ; Do, Diana V. ; Haller, Julia A. ; Pili, Roberto ; Zimmer-Galler, Ingrid E. ; Janjua, Kashif ; Symons, R. C Andrew ; Campochiaro, Peter A. / Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration. In: American Journal of Ophthalmology. 2008 ; Vol. 145, No. 2.
@article{f32bf1bbdc694bf5b60a84eedd074e7e,
title = "Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration",
abstract = "Purpose: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration. Design: Nonrandomized clinical trial. Methods: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV. Results: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 μm. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement from baseline (P = .005), median foveal thickness was 248 μm representing a 72{\%} reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91{\%}, 88{\%}, and 87{\%}), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43{\%}. Conclusions: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.",
author = "Nguyen, {Quan Dong} and Shah, {Syed Mahmood} and Gulnar Hafiz and Do, {Diana V.} and Haller, {Julia A.} and Roberto Pili and Zimmer-Galler, {Ingrid E.} and Kashif Janjua and Symons, {R. C Andrew} and Campochiaro, {Peter A.}",
year = "2008",
month = "2",
doi = "10.1016/j.ajo.2007.09.025",
language = "English (US)",
volume = "145",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration

AU - Nguyen, Quan Dong

AU - Shah, Syed Mahmood

AU - Hafiz, Gulnar

AU - Do, Diana V.

AU - Haller, Julia A.

AU - Pili, Roberto

AU - Zimmer-Galler, Ingrid E.

AU - Janjua, Kashif

AU - Symons, R. C Andrew

AU - Campochiaro, Peter A.

PY - 2008/2

Y1 - 2008/2

N2 - Purpose: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration. Design: Nonrandomized clinical trial. Methods: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV. Results: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 μm. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement from baseline (P = .005), median foveal thickness was 248 μm representing a 72% reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91%, 88%, and 87%), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43%. Conclusions: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.

AB - Purpose: To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration. Design: Nonrandomized clinical trial. Methods: Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV. Results: Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters read at 4 meters (20/80) and median foveal thickness was 346 μm. At the primary endpoint (24 weeks), median VA was 48.5 letters (20/32), representing four lines of improvement from baseline (P = .005), median foveal thickness was 248 μm representing a 72% reduction in excess foveal thickness (P = .007). Four of nine patients had complete elimination of fluorescein leakage, three had near complete elimination (reductions of 91%, 88%, and 87%), two had modest reductions, and one had no reduction. All patients except one showed a reduction in area of CNV with a median reduction of 43%. Conclusions: Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.

UR - http://www.scopus.com/inward/record.url?scp=38349136548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349136548&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.09.025

DO - 10.1016/j.ajo.2007.09.025

M3 - Article

VL - 145

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 2

ER -